Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
March 13, 2022 17:53 ET
|
Ascendis Pharma
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically significant...
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update
March 02, 2022 16:01 ET
|
Ascendis Pharma
- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter -...
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2
February 25, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at...
Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global...
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency
January 13, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin...
Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key...
Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan...
Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline
December 14, 2021 08:00 ET
|
Ascendis Pharma
–– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022 –– Enrollment completed in Phase 2...
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
December 07, 2021 17:41 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on...
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
November 18, 2021 16:42 ET
|
Ascendis Pharma
–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE...